Advanced Oncotherapy (AVO) – Senior Management Appointments

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Michel Baelen has joined the Company as Head of Regulatory Affairs and Gerardo d’Auria has been appointed as a new Technical Director with immediate effect. Michel Baelen holds a Doctorate in management sciences from France and is graduated in Electrical […]

Advanced Oncotherapy (AVO) – Rocket Science – All Set for Take-off

A research note from Beaufort Securities. A small, young company with limited financial resources, trying to take on giant, established international peers with exceptionally deep pockets, in a product area that both tests the limits of scientific understanding whilst also facing the scrutiny of the world’s most exhaustive regulators? Sounds like a recipe for disaster! […]

Advanced Oncotherapy (AVO) – Recent article and Speculative Buy rating from Beaufort Securities

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, yesterday made two important announcements. One being the realignment of roles and responsibilities of the Executive team, the other being a prospectively far reaching industrialisation agreement with Thales, the giant and highly prestigious French multinational technology design and manufacturing group. 1) The agreement […]

Advanced Oncotherapy (AVO) – Holdings in Company

Aviva Plc and it’s subsidiaries announces a change in voting rights. From 83,873,902 shares directly owned, the group now has a direct interest of 56,693,779 shares (3.99%), an indirect interest of 25,998,794 shares (1.84%) and a right of recall to loaned shares of 1,163,720 (0.08%). Total number of voting rights are 83,856,293 shares (5.91%).

Advanced Oncotherapy (AVO) – Directorate Change

Advanced Oncotherapy plc (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that following the continued successful development of the Company’s first LIGHT system and the recent industrialisation agreement with Thales, the Board has decided to realign the roles and responsibilities of the Executive team to add additional focus to both operational […]

Advanced Oncotherapy (AVO) – Thales industrialisation agreement

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has entered into an industrialisation agreement with Thales, for its proprietary LIGHT system. This agreement with Thales provides Advanced Oncotherapy with the support needed to move from the first LIGHT system, currently being developed for use at the Company’s flagship […]

Advanced Oncotherapy – Change of name of NOMAD & Joint Broker

Change of name of Nominated Adviser and Joint Broker   The Company notifies that its Nominated Adviser and Joint Broker has changed its registered name from Westhouse Securities Limited to Stockdale Securities Limited. Advanced Oncotherapy Plc www.avoplc.com Sanjeev Pandya, CEO Tel: +44 20 3617 8728 Nicolas Serandour, CFO Stockdale Securities (Nomad & Joint Broker) Antonio […]

Hardman & Co – Advanced Oncotherapy (AVO) – China- an emerging opportunity

Advanced Oncotherapy (AVO) – Focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN facility in Switzerland. Commercial momentum is building, having recently secured a second purchase order in China, formed a JV with Circle to operate potentially the first proton therapy facility […]